Astellas Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Astellas Pharma sits in the top decile of US sponsors by registered trial count (#179 of 15,742 sponsors by registered trial count).
Astellas Pharma: 165 sponsored US clinical trials, 2 recruiting.
Astellas Pharma sponsors 165 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 143 completed. 47 of these trials are in Phase 3-4 (later-stage) and 113 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Candidemia, with 4 trials.
Top-decile sponsor footprint
Astellas Pharma ranks in the top decile of sponsors by registered trial count (#179 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
143 of 162 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
165 total, page 4 of 4
Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis
NCT00692172
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
NCT00072618
Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection
NCT00885820
Study Using CP-461 to Treat Advanced Prostate Cancer
NCT00036075
Study of CP-461 in Patients With Advanced Renal Cell Cancer
NCT00036036
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00073489
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
NCT00085826
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
NCT00044057
A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients
NCT00044070
A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients
NCT00650468
A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
NCT00510913
A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
NCT00293891
A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
NCT00293930
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
NCT00257478
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
NCT00048659
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 59 |
| Phase 2 | 54 |
| Phase 3 | 28 |
| Phase 4 | 19 |
Therapeutic Areas
What is open in the Astellas Pharma pipeline
2 recruiting of 165 indexed (1% open); 143 completed (87%).
Phase mix: 47 late (III/IV) vs 113 early (I/II) (early-phase heavy).
Top condition: Candidemia (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Astellas Pharma: open-pipeline peers nationwide
Peers matched on 165 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Astellas Pharma sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 165 trials (± recruiting share)
- Teva Branded Pharmaceutical Products R&D · 167 trials · 4% recruiting
- Wyeth is now a wholly owned subsidiary of Pfizer · 167 trials · 0% recruiting
- Temple University · 163 trials · 13% recruiting
- Tufts University · 163 trials · 6% recruiting
Sponsors near 1% open enrollment (± trial volume)
- University of New Mexico · 1% recruiting · 168 trials
- Abbott Nutrition · 1% recruiting · 89 trials
- Baxalta now part of Shire · 1% recruiting · 74 trials
- Power Life Sciences · 2% recruiting · 62 trials
Related
What to do with this Astellas Pharma page
165 registered trials is a research-attention snapshot, not an endorsement of Astellas Pharma or any single study.
- 2 of Astellas Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Candidemia is the condition Astellas Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Candidemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Astellas Pharma pipeline card: 165 registered trials from official public datasets.Report a data error.